The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.

The iCAR-T platform was originally developed through a collaboration between Takeda and Kyoto University’s Center for iPS Research and Application (CiRA). The first CAR-T cell therapy created ...

Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

Global Cell Therapy market is driven by increasing demand for advanced therapies in oncology, regenerative medicine, and immunology. The market's expansion is also fueled by continuous innovations in ...

Takeda, a global leader in biopharmaceutical innovation ... donor experience solutions to expand personalized healthcare solutions in plasma-based therapy. The offering of data science and ...

In this example, the treatment is a novel gastrointestinal (GI) therapy marketed by Takeda. Whilst suitable patients are dispersed across multiple care settings, due to its unique administration and ...

Takeda is promoting U.S. chief Julie Kim to be ... The first phase of expansion at the Danish plant just added six new mammalian cell bioreactors, and the next phase is being backed by $1.6 ...

WHO clears Takeda's dengue vaccine May 15, 2024 The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three ...